Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CRVO | 8-K | bearish | 6/10 | CervoMed closed a $10M registered direct offering of 2.5M shares at $4.00/share, priced at-the-market under Nasdaq rules | Jun 22, 2026 |
| DYN | 8-K | neutral | 2/10 | Dyne Therapeutics elected Barry E. Greene as an independent Class I director to its board. This is a routine board appoi | Jun 22, 2026 |
| SEPN | 144 | neutral | 4/10 | Jae Kim, an officer of Septerna, filed a Form 144 to sell 94,339 shares valued at approximately $3.3 million. The sale s | Jun 22, 2026 |
| PRFX | F-1 | bearish | 7/10 | PRF Technologies filed an F-1 registration statement to register up to 7,500,000 ordinary shares for resale by selling s | Jun 22, 2026 |
| GPRE | S-3ASR | neutral | 4/10 | Green Plains filed an automatic shelf registration (S-3ASR) to register 550,000 shares of common stock underlying warran | Jun 22, 2026 |
| LEGN | 6-K | bearish | 5/10 | Legend Biotech priced a $226M public offering of 7,700,000 ADSs at $29.35 per ADS, with a 30-day underwriter option for | Jun 22, 2026 |
| DFTX | 424B5 | bearish | 7/10 | Definium Therapeutics filed a preliminary 424B5 prospectus supplement for a $500 million underwritten public offering of | Jun 22, 2026 |
| RDHL | 6-K | mixed | 6/10 | RedHill Biopharma closed a private placement raising $6M in upfront gross proceeds (with up to ~$13.4M additional from w | Jun 22, 2026 |
| ELVN | 144 | neutral | 2/10 | OrbiMed Advisors LLC filed a Form 144 notice of intent to sell 26,323 shares of Enliven Therapeutics (ELVN), held by its | Jun 22, 2026 |
| RYTM | 144 | neutral | 2/10 | Director Lynn Tetrault filed a Form 144 to sell 37,000 shares via option exercise, valued at approximately $3.58 million | Jun 22, 2026 |
| CGON | 144 | neutral | 3/10 | CG Oncology director Leonard Post filed a Form 144 indicating intent to sell 6,000 shares (~$366K) under a 10b5-1 plan, | Jun 22, 2026 |
| ELVN | 144 | bearish | 7/10 | OrbiMed Advisors LLC, through OrbiMed Private Investments VII, LP, filed a Form 144 notice of intent to sell approximate | Jun 22, 2026 |
| CTMX | 8-K | neutral | 3/10 | CytomX Therapeutics filed an 8-K reporting the results of its June 17, 2026 Annual Meeting. Stockholders approved a char | Jun 22, 2026 |
| ELVN | 144 | neutral | 2/10 | OrbiMed Capital LLC (portfolio manager for The Biotech Growth Trust PLC) filed a Form 144 indicating intent to sell appr | Jun 22, 2026 |
| RLAY | 144 | neutral | 3/10 | Donald Bergstrom, an officer of Relay Therapeutics, filed a Form 144 notice of intent to sell up to 110,646 shares of co | Jun 22, 2026 |
| PHGE | DEFA14A | neutral | 2/10 | BiomX Inc. filed a DEFA14A supplement correcting an error in its proxy statement: the Audit Committee did not appoint Ke | Jun 22, 2026 |
| CBIO | 10-Q/A | neutral | 3/10 | Crescent Biopharma filed a Form 10-Q/A to add previously omitted Rule 10b5-1 trading arrangement disclosures for its CEO | Jun 22, 2026 |
| ORKA | CLUSTER | neutral | 3/10 | Five Oruka Therapeutics insiders, including the CEO, CMO, COO, General Counsel, and SVP Finance, sold a total of $396K i | Jun 22, 2026 |
| CELZ | PRESS-RELEASE | bullish | 6/10 | Creative Medical Technology announced FDA clearance to expand its ADAPT Phase 2 trial of CELZ-201 (Olastrocel) for chron | Jun 22, 2026 |
| ALLR | 8-K | neutral | 2/10 | Allarity Therapeutics filed an 8-K announcing a Trial-in-Progress poster presentation for its Phase 2 stenoparib trial a | Jun 22, 2026 |
| CRDF | CLUSTER | bullish | 4/10 | Two insiders at Cardiff Oncology, including the CEO, made open-market purchases totaling $66K on June 18, 2026. While th | Jun 22, 2026 |
| KALV | 15-12G | bearish | 7/10 | KalVista Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g), effective June 22, 2 | Jun 22, 2026 |
| CMND | PRESS-RELEASE | bullish | 6/10 | Clearmind Medicine announced the successful completion of treatment for all 24 participants in Part A of its Phase I/II | Jun 22, 2026 |
| PVLA | PRESS-RELEASE | bullish | 7/10 | Palvella Therapeutics announced that the FDA has granted rolling review for its NDA for QTORIN™ rapamycin to treat micro | Jun 22, 2026 |
| BBIO | PRESS-RELEASE | neutral | 4/10 | BridgeBio announced additional positive data from the Phase 3 PROPEL 3 study of oral infigratinib in achondroplasia will | Jun 22, 2026 |
| REGN | PRESS-RELEASE | bullish | 7/10 | Regeneron announced FDA and EMA acceptance of regulatory applications for cemdisiran, an investigational siRNA therapy f | Jun 22, 2026 |
| NRXP | PRESS-RELEASE | neutral | 4/10 | NRx Pharmaceuticals announced FDA approval of an Expanded Access Protocol for NRX-101 (D-cycloserine/lurasidone) to augm | Jun 22, 2026 |
| TCRX | PRESS-RELEASE | bullish | 7/10 | TScan Therapeutics presented positive Phase 1 Cohort C data for TSC-101, showing 11 of 14 patients achieved complete don | Jun 22, 2026 |
| LODE | PRESS-RELEASE | bullish | 6/10 | Comstock Inc. announced the sale of 100% of its mining and mineral assets to Mackay Precious Metals Inc. for over $45 mi | Jun 22, 2026 |
| HCWB | EFFECT | neutral | 5/10 | HCW Biologics' S-1 registration (File No. 333-296577) became effective on June 18, 2026, enabling selling stockholders t | Jun 22, 2026 |